• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Biofourmis Analytics Engine Receives FDA Clearance for Ambulatory Physiologic Monitoring

by Fred Pennic 10/04/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Biofourmis AI Analytics Engine Receives FDA Clearance for Ambulatory Physiologic Monitoring

– Biofourmis received 510(k) clearance from the FDA for its Analytics Engine as a medical device for ambulatory physiological monitoring.

– Milestone approval establishes an AI-powered solution as the foundation for future disease-specific predictive management tools from Biofourmis.

– This FDA approval is the second market authorization for Biofourmis, having earned the agency’s approval in May 2019 for its Biovitals RhythmAnalytics platform.

Boston-based Biofourmis has received 510(K) clearance for its machine-learning and artificial intelligence (AI)-powered analytics engine as a medical device for ambulatory physiological monitoring. This regulatory approval is part of the FDA’s growing recognition of machine-learning and AI in the Software as a Medical Device category.  

This emerging category of medical devices is on trend from a strategic business standpoint too: A recent Deloitte report found that even medtech companies that have traditionally focused on developing hardware (e.g., surgical equipment, joint replacements, diagnostic equipment, infusion pumps, pacemakers, etc.) are shifting their focus to software, data collection, and advanced data analysis.

An Important Tool in the Move to Value-Based Care

The Biovitals Analytics Engine receives physiologic data such as heart rate, respiratory rate and activity in near real-time from FDA-cleared sensors and leverages AI and machine learning to identify the correlation between multiple vital signs and the patient’s daily activities, building an individualized biometric signature that is dynamically updated based on incoming data. The Biovitals Analytics Engine computes a time series Biovitals Index, which alerts providers to changes in patients’ measured vital signs from their baseline—a precursor to decompensation that in some cases may be up to a few weeks before an event would have occurred without any intervention. This advance notice provides ample time for the clinician to take the necessary clinical steps to change the trajectory of the disease.

The Biovitals platform can potentially reduce hospital readmissions and decreases the need for emergency department (ED) visits. The real-world insights generated from the AI-powered Biovitals™ Analytics Engine also provide a foundation for pharmaceutical researchers and medical device manufacturers to develop more effective solutions—in less time and with smaller investments, thanks to more rapid and reliable clinical insights.

Biovitals Analytics Engine Use in Research Partnerships

The Biovitals Analytics Engine is also currently in use for research initiatives involving patients with heart failure. One research partnership is with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). BiovitalsHF, which is powered by the Biovitals Analytics Engine is being used in this study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these patient-centric measures in the drug approval process.

Biovitals Analytics Engine Proven in Real-World Settings

Biofourmis’ application was based on clinical studies involving monitoring patients with complex chronic conditions such as heart failure, COPD and atrial fibrillation—at-home, in a real-world setting. In one study, the Biovitals Analytics Engine enabled earlier clinical intervention by predicting heart failure decompensation 12 days in advance of a heart failure-related hospitalization in a 73-year-old man—who had multiple comorbidities, including hypertension, COPD and diabetes—by combining multivariate physiology signals to generate actionable insight for clinicians to intervene.

Another case was a 68-year-old man, also with multiple comorbidities. The intelligence generated from the Biovitals Analytics Engine alerted clinicians about a lack of medication regimen adherence, which resulted in an ED visit, but clinicians were able to avoid a hospital admission with changes to the patient’s medication in the ED setting.

Foundation for Digital Therapeutics Product Pipeline

This FDA approval is the second market authorization for Biofourmis, having earned the agency’s approval in May 2019 for its Biovitals™ RhythmAnalytics™ platform, which is cloud-based software for automated interpretation of more than 15 types of cardiac arrhythmias. The newly cleared Analytics Engine is a much broader approval to process multiple physiology signals, as the technology serves as the foundation for all of Biofourmis’ digital therapeutics product pipeline.

“This milestone approval is foundational to the Biovitals™ ecosystem, which includes not only our most advanced solution, BiovitalsHF™ for heart failure—but also our range of solutions across therapeutic areas, such as pain, oncology, sleep disorders and others in development,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “Receiving this important regulatory approval will only accelerate the development and commercialization of these innovative digital therapeutic solutions.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Biofourmis, Digital Therapeutics, FDA clearance 510k, FDA Cleared Devices, Machine Learning

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

How to Build Hybrid Care Models Around Remote Patient Monitoring

How to Build Hybrid Care Models Around Remote Patient Monitoring

Most Popular

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

How AI Can Eliminate Surprise Bills, Improve Payment Integrity

AI Can Eliminate Surprise Bills, Improve Payment Integrity

Q/A: IQVIA’s Global Lead Talks Unlocking AI for Drug Repurposing

M&A: Kaiser Acquires Geisinger, Forms Risant Health

5 Executives Weigh in on VBC Impact on Kaiser/Geisinger Deal

Digital Health Executive Hires & Departures

Digital Health Executive Hires & Departures: Ed Marx Departure, Particle Health CEO, Rhapsody CFO, Others

Catalyst by Wellstar Launches $100M Digital Health Venture Fund

Catalyst by Wellstar Launches $100M Digital Health Venture Fund

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |